GU Cancers 2019 | ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancer

Ian Davis

Ian Davis, FRAChPM, FRACP, MBBS, PhD, of the Monash University Eastern Health Clinical School, Melbourne, Australia speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He summarizes the results of the Phase III ARCHES trial (NCT02677896) that were presented at the meeting. This study investigated androgen deprivation therapy (ADT) with enzalutamide or a placebo in metastatic hormone-sensitive prostate cancer (mHSPC).

Share this video  
Similar topics